Flint et al.

1

- 1 Title: Topical Probiotics Decrease the Severity of Atopic Dermatitis. A Systematic Review and
- 2 Meta-Analysis of Double-Blind, Randomized, Placebo Control Trials
- 3
- 4 Elliot Flint¹, Nabeel Ahmad MSEd¹, Kevin Rowland PhD¹, Charles Hildebolt PhD^{2*},
- 5 David Raskin PhD¹
- 6 ¹Tilman J Fertitta Family College of Medicine, University of Houston, Houston, TX, and
- 7 ²Department of Anthropology, Washington University in St. Louis, St. Louis, WI
- 8

9 Corresponding author: David Raskin, Ph.D. Tilman Fertitta Family College of Medicine,

- 10 University of Houston, 5055 Medical Circle, Houston, TX 77204-6064, USA Email:
- 11 [draskin@central.uh.edu]

12 ABSTRACT

13 Atopic Dermatitis (AD) is a chronic skin disease that commonly appears during childhood 14 but can present at any age. There are many reports showing that probiotics relieve AD 15 symptoms in children. This systematic review and meta-analysis sought to determine the 16 efficacy of topical probiotic treatment for AD in adult populations. A database search was 17 conducted of peer-reviewed, double-blind clinical trials, and studies underwent a systematic 18 exclusion and inclusion process, yielding four that met the criteria. Disease severity, as 19 measured by a standardized scoring tool (SCORAD), was collected, and compared to placebo 20 at two-week and four-week time points. All studies showed improvement in SCORAD in the 21 treatment groups compared to baseline at all time points. Two showed significant decreases 22 in SCORAD after two weeks of treatment, and three studies showed long-lasting 23 improvement after four weeks of treatment. Interestingly, while each study showed a 24 reduction in severity of AD at the two- and four-week time points, a pooled meta-analysis did 25 not show a statistically significant difference between treatment and control at four weeks of 26 treatment. Clinically, there may be benefits to topical probiotic usage as evidenced by the 27 individual studies, more studies need to be performed including adults to show statistical 28 significance.

Flint et al.

2

30 INTRODUCTION

31 Atopic dermatitis (AD) is an inflammatory skin disorder that often appears in early childhood, affecting approximately 8 - 12% of children¹. AD can become a chronic 32 condition, extending into adulthood, with 6 - 9% of U.S. adults affected¹. An isolated cause 33 34 has not been identified; however, a combination of family history, loss of function in the 35 filaggrin (FLG) protein, which helps maintain the integrity of the skin, and exogenous 36 environmental triggers, such as dust mites, heat, dry or humid climate, may play a role in its 37 development². The skin of AD lesions is characterized by microbial dysbiosis, with a 38 reduction of diversity and overrepresentation of Staphylococcus aureus, correlating with increased lesion infection and flare-ups³. The normal microbiomes of the gut and the skin 39 40 may produce molecules that inhibit the growth of S. aureus, and they interact with the immune system to downregulate inflammatory responses^{4,5}. Given the relationship between 41 42 the skin microbiome and AD, investigations into the use of adjuvant probiotics are warranted. 43 Probiotics are living organisms that provide health benefits when consumed or applied to the 44 body. Several systematic reviews have studied the effects of oral probiotics and their effect 45 on decreasing AD severity in adult and pediatric populations. Such reviews explored various 46 oral probiotic strains of Bifidobacterium, Lactobacillus, and/or Streptococcus with most trials concluding a reduction in the Scoring Atopic Dermatitis (SCORAD) index⁶⁻¹². 47

48 There is a growing body of research investigating the effectiveness of probiotics on reducing 49 the severity of AD. Most of these studies use oral probiotics and many test effectiveness only 50 in children. There have been fewer studies using topical probiotics and testing their 51 effectiveness in adults. Thus, a systematic review of randomized control trials of topical 52 probiotics is needed to establish the validity of existing research regarding treating AD. To 53 date, there has been no systematic review of topical probiotics for AD. In this systematic 54 review, we explored the literature on topical probiotics' role in decreasing AD in adult and 55 pediatric populations. We performed a meta-analysis of the reported data to evaluate the 56 effectiveness of the topical probiotics on reducing AD severity.

57 MATERIALS AND METHODS

58 Study Design

Flint et al.

3

60 Web of Science and PubMed were searched using the terms (atopic dermatitis OR eczema) 61 AND (probiotic* OR synbiotic*). After removing duplicates, the titles and abstracts of 979 62 articles were screened by two reviewers (EF and NA). Reviewers voted to exclude articles or 63 advance them to the next stage of the review using the inclusion and exclusion criteria listed 64 in Table 1. Reviewers' decisions were blinded to one another and organized by the systematic 65 review software Rayyan (Qatar Computing Research Institute). Any article that received that 66 did not receive two votes to "exclude" was advanced to the next stage of the screening 67 process (n=80). Article retrieval and screening of the full text of studies was done by four 68 reviewers (EF, NA, DR, and KR). Each article was reviewed by two reviewers and voted to 69 include or exclude based on the eligibility criteria. Conflicts between reviewer decisions were 70 resolved by group consensus of the four reviewers. At the end of the screening process, only 71 one article met the eligibility criteria for inclusion in the review. To expand the pool of 72 eligible studies, the reviewers eliminated "Study subjects of 18 years or older" as part of the 73 eligibility criteria. Articles were screened using the same process as above, and three 74 additional articles were identified for inclusion in the review. Fig 1 highlights the preferred 75 reporting items for systematic reviews and meta-analysis (PRISMA).

76

77 Data Extraction

Data was extracted from the included articles by one reviewer (EF). Data extracted from each article included the probiotic(s) used, the study's duration, the days at which treatment effects were measured, and the age of the study subjects. Raw data of SCORAD values were not included in the Axt-Gadermann study, so SCORAD values were obtained using the software NIH Image J to estimate values reliably based on graphs provided by the paper¹³.

83

84 Statistical Analysis

85 Meta-analyses were performed for three time periods: (1) baseline, (2) two weeks, and four 86 weeks. The intervals at which outcomes were measured varied slightly between studies. For 87 our analysis, measurements taken on days 0 and 1 were grouped as "baseline." Days 14 and 88 15 were grouped as "two weeks," and days 28, 29, or 30 were grouped as "four weeks." Four 89 studies were used for the baseline assessments, two for the two-week assessments, and three 90 for the four-week assessments. The standardized difference in means was used as the effect 91 size index. Because we assumed that the studies in each analysis represented a random 92 sample from the universe of potential studies, we employed a random-effects model for each 93 analysis, with each analysis being used to make an inference to the universe of potential

Flint et al.

4

94 studies. In support of our using a random-effects model, we provide the following two 95 statements from a book on meta-analysis. "When studies are pulled from the literature, a 96 random-effects model should be used because common sense indicates that the true effect size varies across studies"¹⁴; and "This model assumes that the studies in the analysis are 97 representative of a universe of comparable studies, and that the results of the analysis will be 98 99 generalized to that universe¹⁴." In addition, one of our goals was to create a prediction interval for each time period, and the creation of a prediction interval requires the use of a 100 101 random-effects model. As indicated in another recently published book¹⁵, a prediction interval includes the true effect size for 95% of all populations in the universe." In this book, 102 the importance of prediction intervals in meta-analyses is stressed.¹⁵ and an article¹⁶ is cited 103 that makes a plea for routinely presenting prediction intervals in meta-analyses; therefore, to 104 105 help interpret the results of our meta-analysis, a prediction interval (which is based upon the 106 random-effects model) was calculated for each time. "The prediction interval reflects the 107 variation in treatment effects over different settings, including what effect is to be expected in future patients..."¹⁶ "(More accurately, in 95% of all meta-analyses the mean effect size will 108 fall within the confidence interval.)"¹⁴ As explained in this cited book: The 95% confidence 109 110 interval for a fixed-effect model tells us that the mean prevalence in the set of studies falls 111 with this range, and the 95% confidence interval for a random-effects model tells us that the 112 mean in the universe of comparable populations falls with this range; whereas, the 95% 113 prediction interval tells us that the prevalence in any single population can be as low or as high as the lower limit and the upper limit of the interval 14 . 114

115

For our meta-analysis, the standardized mean difference (SMD) for a fixed-effect model was calculated with Hedges g statistic,¹⁷ and the heterogeneity statistic was used to calculate the summary standardized mean difference for a random effects model¹⁸. "If the value 0 is not within the 95% confidence interval (CI), the SMD is statistically significant at the 5% level (P < 0.05)¹⁹." "Cohen's rule of thumb for interpretation of the SMD statistic is: a value of 0.2 indicates a small effect, a value of 0.5 indicates a medium effect and a value of 0.8 or larger indicates a large effect¹⁹."

123

124 Alpha was set at 0.05; however, Amrhein et al. emphasized that the clinical importance of

125 findings, not their statistical significance, be emphasized,²⁰ and for the interpretation of

126 results of our meta-analysis, the clinical importance of findings are emphasized. For our

127 meta-analysis, the standardized mean difference (SMD) for a fixed-effect model was

Flint et al.

5

128	calculated with Hedges g statistic, ¹⁷ and the heterogeneity statistic was used to calculate the
129	summary standardized mean difference for a random effects model ¹⁸ . "If the value 0 is not
130	within the 95% confidence interval (CI), the SMD is statistically significant at the 5% level
131	$(P < 0.05)^{20}$." "Cohen's rule of thumb for interpretation of the SMD statistic is a value of 0.2
132	indicates a small effect, a value of 0.5 indicates a medium effect and a value of 0.8 or larger
133	indicates a large effect ¹⁹ ." We performed our meta-analysis with Comprehensive Meta-
134	Analysis Version 4 ²¹ .
135	

136

137 **RESULTS**

Our search strategy yielded four articles that met the inclusion criteria²²⁻²⁵ (Table 2). Articles
tested the use of probiotics in treating atopic dermatitis, although different timelines were
used for testing.

141 SCORAD

142 SCORAD is a standardized scoring tool to rate the severity of atopic dermatitis by physician 143 and patient ratings of pruritis, dryness, and redness. Higher SCORAD values indicate more 144 severe symptoms, whereas a low SCORAD indicates milder disease severity. In the articles 145 that were included in our analysis, the percent change in SCORAD demonstrated reduced 146 eczema severity with the use of probiotics in all four studies (Fig 2a), whereas placebos only 147 reduced eczema severity in two of the four studies (Fig 2b). The percent change in SCORAD 148 from the probiotic groups was subtracted from the percent change in placebo at each 149 respective time point and graphed; positive values indicate that the probiotics outperformed 150 the placebo at that charted point (Fig 2c). This figure demonstrates how probiotics 151 outperformed placebos across all studies, except for the Butler et al. study at 28 days. It 152 should be noted, however, that the Butler study showed a benefit from the probiotics 153 compared to placebo later in the study at 56 days.

154 Meta-analysis

155 Meta-analyses were performed for the placebo and probiotic treatment groups. For the

- baseline data, the mean effect size is 0.372 with a 95% confidence interval of -0.021 to 0.765
- 157 (Fig 3a). The mean effect size in the universe of comparable studies could fall anywhere in

Flint et al.

6

158 this interval. The Z-value tests the null hypothesis that the mean effect size is zero. The Z-159 value is 1.854 with p = 0.064. Using a criterion alpha of 0.050, we cannot reject this null 160 hypothesis of no effect. If the true effects are normally distributed (in g units), an estimate of 161 the prediction interval is -0.889 to 1.633 (Fig 3a). The true effect size in 95% of all 162 comparable populations falls in this interval. 163 164 These calculations for baseline data included only four studies. It has been suggested that ten 165 studies are a useful minimum for a meta-analysis15. Therefore, estimates of heterogeneity 166 based on less than ten studies may not be reliable. A prediction interval and other functions 167 could not be performed for the two-week data because a minimum sample size of 3 is 168 required, and for the two-week assessments, there were only two studies. For the two-week 169 data, the mean effect size is -3.700 with a 95% confidence interval of -10.481 to 3.0815 (Fig. 170 3b). The mean effect size in the universe of comparable studies could fall anywhere in this 171 interval. The Z-value is -1.069 with p = 0.285, which does not reject the null hypothesis of no 172 effect. For the four-week data, the mean effect size for the three studies is -0.292 with a 95% 173 confidence interval of -0.904 to 0.321 (Fig 3c). The mean effect size in the universe of 174 comparable studies could fall anywhere in this interval. The Z-value is -0.934 with p = 0.350. 175 Using a criterion alpha of 0.050, we cannot reject this null hypothesis of no effect. An 176 estimate of the prediction interval is -7.221 to 6.637 (Fig 4b). The true effect size in 95% of 177 all comparable populations falls in this interval. These calculations for four-week data 178 included only three studies; therefore, heterogeneity estimates may not be reliable. 179 180 To summarize the results of our assessments, none of our meta-analyses rejected the null 181 hypothesis of no effect ($p \ge 0.064$). The prediction interval at baseline indicated that with 182 treatment, many future patients would experience benefits; however, at four weeks, the 183 prediction interval indicated that it would be essentially a coin toss as to whether a future

185 for baseline, two weeks, and four weeks were small—respectively, four studies, two studies,

patient would experience a benefit. A limitation of our assessments is that our sample sizes

and three studies.

Flint et al.

7

187 DISCUSSION

188 AD lesions show an increased abundance of S. aureus and reduced diversity of the skin 189 microbiome3,5. Due to a lack of long-term, effective AD treatments, there has been interest 190 in modifying the skin microbiome using probiotics. Probiotics are easily assembled, 191 relatively inexpensive, and can be purchased without a prescription, representing a practical 192 avenue of treatment for individuals afflicted with AD. We performed a systematic review and 193 meta-analysis of studies that investigated the use of topically applied probiotics for AD 194 treatment. Overall, only a few studies met our inclusion criteria. The included studies 195 demonstrate a benefit of probiotic application in treating atopic dermatitis as measured by a 196 standard scoring system (SCORAD); however, that benefit varied at the different time points

197 measured.

198 This systematic review had multiple challenges. Initially, we tried to perform a review of AD 199 in adults, but there were not enough studies to carry that out. We modified the criteria to 200 accept studies that included both children and adults. Even so, only four studies met the 201 criteria. These studies used different probiotic formulations and different study periods. The 202 meta-analysis showed a beneficial effect at two weeks but not at four weeks. The one study 203 with enough participants to show the non-effect at four weeks showed a beneficial effect at 204 eight weeks, suggesting that topical probiotics are effective, but effects may be better 205 appreciated in studies of longer durations. Until more clinical trials are performed using 206 standardized treatments and treatment lengths, it will be challenging to determine the 207 effectiveness of topical probiotics. The one study that showed little effect on SCORAD for up 208 to four weeks used a probiotic with only a single organism, *Lactobacillus reuteri*²³. Two of 209 the other studies used Vitreoscilla filiformis, and one study used a symbiotic, a mix of several 210 bacterial species, along with a prebiotic (Table 1). Future studies should focus on probiotics 211 that show effectiveness, and while there are only two studies, V. *filiformis* is promising as a probiotic treatment for $AD^{24,25}$. 212

Flint et al.

214 Atopic dermatitis commonly affects infants and young children, but adults are affected as well, with as many as 10% of adults reporting $eczema^{26,27}$. The gut microbiome has been 215 216 linked with skin health and may be important in preventing inflammatory processes associated with AD^{28,29}. Probiotics may interfere *with S. aureus* growth through directly 217 218 killing S. aureus, or occupying niches in the skin preventing S. aureus from colonizing. 219 Decreasing S. aureus growth on the skin could increase diversity and reduce inflammation. 220 Clinical trials using oral probiotics to modify the gut microbiome have been performed, but in adults, oral probiotics have shown mixed effects^{30,31}. Using oral probiotics on those with 221 222 mature gut microbiomes might not be as effective compared to using them for infants or 223 young children. Our systematic review evaluated topical probiotics to determine whether

there was an effective treatment for adults.

225 A recent systematic review analyzed many AD treatments, including oral and topical 226 probiotics, topical emollients, biologics, pharmaceuticals, and many other therapies³⁰. They 227 found that treatments across the spectrum had positive effects on AD outcomes. Oral 228 probiotics generally improved AD severity in children and adults, although some studies in 229 children showed no effect. They found that topical probiotics generally improved AD, but 230 they also included non-clinical trials in their results. They also found that there were 231 significant benefits from biologics. Our systematic review and meta-analysis used only 232 double-blind, randomized clinical trials, and all studies we analyzed included adults. We 233 found that while there was a general reduction in SCORAD from topical probiotic use in 234 three out of four studies, we could not reject the null hypothesis, that the treatment had no 235 effect at four weeks. This is consistent with other research. Greenzaid et al. found that most 236 of the reported studies show a positive effect on SCORAD or other indicators of AD, but 237 there were also studies showing no effect. Many treatment studies show a benefit to AD 238 patients, but the mixed results show that there is a need to determine which treatments work, 239 why they work, and the appropriate length of treatment. For probiotics, there are a variety of 240 different bacteria that are administered, and there are a variety of vehicles to carry the 241 bacteria. Future studies need to determine the most effective treatments.

Flint et al.

- An advantage of topical probiotic treatment is that it is low-cost, easy to administer, and has
- 243 few adverse effects. Using biologics or pharmaceuticals will be more costly. Oral
- administration of probiotics carries a greater risk of non-adherence to treatment. All four
- 245 clinical trials we identified that used topical probiotics in randomized, double-blind studies
- show positive effects over the length of the trial. Our meta-analysis showed that this
- treatment is only effective over the first two weeks of treatment. Because endpoints varied
- between studies, the longest common endpoint, four weeks, was analyzed and showed no
- significant effect. We recommend that additional clinical trials be performed using the
- treatments that look successful (break out which probiotics were successful vs not), using
- 251 more patients over a longer period to determine treatments that will be effective enough for
- 252 widespread use.

253 ACKNOWLEDGEMENTS

- **Funding sources:** n/a
- 255 **Conflict of Interest Disclosures:** the authors declare no conflicts interest
- 256 IRB approval status: n/a
- 257

Flint et al

10

REFERENCES

1. Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. J Invest Dermatol 2019; 139: 583-590.

2. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70: 338-351.

3. Notay M, Foolad N, Vaughn AR, Sivamani RK. Probiotics, Prebiotics, and Synbiotics for the Treatment and Prevention of Adult Dermatological Diseases. Am J Clin Dermatol 2017; 18: 721-732.

4. Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from human skin commensal bacteria protect against. Sci Transl Med 2017; 9.

5. Totté JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 687-695.

6. Matsumoto M, Aranami A, Ishige A, Watanabe K, Benno Y. LKM512 yogurt consumption improves the intestinal environment and induces the T-helper type 1 cytokine in adult patients with intractable atopic dermatitis. Clin Exp Allergy 2007; 37: 358-370.

7. Matsumoto M, Ebata T, Hirooka J, Hosoya R, Inoue N, Itami S, et al. Antipruritic effects of the probiotic strain LKM512 in adults with atopic dermatitis. Ann Allergy Asthma Immunol 2014; 113: 209-216.e207.

8. Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S. Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J Immunopathol Pharmacol 2011; 24: 1037-1048.

9. Drago L, De Vecchi E, Toscano M, Vassena C, Altomare G, Pigatto P. Treatment of atopic dermatitis eczema with a high concentration of Lactobacillus salivarius LS01 associated with an innovative gelling complex: a pilot study on adults. J Clin Gastroenterol 2014; 48 Suppl 1: S47-51.

Flint et al

11

10. Moroi M, Uchi S, Nakamura K, Sato S, Shimizu N, Fujii M, et al. Beneficial effect of a diet containing heat-killed Lactobacillus paracasei K71 on adult type atopic dermatitis. J Dermatol 2011; 38: 131-139.

11. Iemoli E, Trabattoni D, Parisotto S, Borgonovo L, Toscano M, Rizzardini G, et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J Clin Gastroenterol 2012; 46 Suppl: S33-40.

12. Roessler A, Friedrich U, Vogelsang H, Bauer A, Kaatz M, Hipler UC, et al. The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clin Exp Allergy 2008; 38: 93-102.

13. Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, et al. ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics 2017; 18: 529.

14. Borenstein M. Common Mistakes in Meta-Analysis and How to Avoid Them: Biostat Inc; 2019.

15. Borenstein M, Hedges V. L, Higgins P.T. J, Rothstein R. H. Introduction to Meta-Analysis, 2nd Edition . . 2nd ed. Wiley, 2021: p. 544.

16. IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 2016; 6: e010247.

17. Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando, Florida ; London, England: Academic Press, Inc; 1985.

18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.

19. Schoonjans F. Medcalc Manual: Easy-to-Use Statistical Software 2017.

20. Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature 2019; 567: 305-307.

21. Borenstein M, Hedges L, Higgins JPT, Rothstein H. Comprehensive Meta-Analysis Version 4. Englewood, NJ, 2022.

22. Noll M, Jäger M, Lux L, Buettner C, Axt-Gadermann M. Improvement of Atopic Dermatitis by Synbiotic Baths. Microorganisms 2021; 9:527.

23. Butler É, Lundqvist C, Axelsson J. DSM 17938 as a Novel Topical Cosmetic Ingredient: A Proof of Concept Clinical Study in Adults with Atopic Dermatitis. Microorganisms 2020; 8:1026.

Flint et al

12

24. Seité S, Zelenkova H, Martin R. Clinical efficacy of emollients in atopic dermatitis patients - relationship with the skin microbiota modification. Clin Cosmet Investig Dermatol 2017; 10: 25-33.

25. Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008; 159: 1357-1363.

26. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 2011; 131: 67-73.

27. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013; 132: 1132-1138.

28. Lee SY, Lee E, Park YM, Hong SJ. Microbiome in the Gut-Skin Axis in Atopic Dermatitis. Allergy Asthma Immunol Res 2018; 10: 354-362.

29. Polkowska-Pruszyńska B, Gerkowicz A, Krasowska D. The gut microbiome alterations in allergic and inflammatory skin diseases - an update. J Eur Acad Dermatol Venereol 2020; 34: 455-464.

30. Greenzaid JD, Chan LJ, Chandani BM, Kiritsis NR, Feldman SR. Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics. Expert Opin Investig Drugs 2024; 33: 415-430.

31. Umborowati MA, Damayanti D, Anggraeni S, Endaryanto A, Surono IS, Effendy I, et al. The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials. J Health Popul Nutr 2022; 41: 37.

Flint et al

13

FIGURE LEGENDS

Fig. 1. PRISMA flow diagram



Flint et al

50

60

40

14

Fig. 2. Percent Change from baseline in SCORAD vs time. A) Percent change in SCORAD vs time for probiotics for all studies. B) Percent change in SCORAD vs time for placebo for all studies. C) Difference in percent change in SCORAD between groups vs time for all studies.



-30.0 -40.0 -50.0 -60.0 3R

0

10

20

30

Days

Flint et al

15

Fig. 3. Summary values for dermatitis, (A) Baseline values for four studies and the pooled values for the random effects model. (B) Two-week values for two studies and the pooled values for the random effects model. (C) Four-week values for four studies and the pooled values for the random effects model.

Study name	Statistics for each study							Hedges's g and 95% Cl				
	Hedges's g	Variance	Lower	Standard error	Upper limit	Z-Value	p-Value					
Axt-Gadermann, 2021	1.418	0.322	0.306	0.568	2.531	2.498	0.012		1	- 1	+	-
Butler et al, 2020	0.380	0.114	-0.283	0.338	1.042	1.123	0.261		- I -	_	-	
Gueniche et al, 2008	0.202	0.076	-0.340	0.277	0.744	0.729	0.466					 1
Seite et al, 2017	0.177	0.085	-0.393	0.291	0.747	0.610	0.542					 I
Pooled	0.372	0.040	-0.021	0.201	0.765	1.854	0.064					-
								-1.00	-0.50	0.00	0.50	1.0
Study name			Statistics	s for each s	tudy				Std diff i	n means an	nd 95% Cl	_
	Std diff in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value					
Axt-Gadermann, 2021	-7.316	1.482	2.19	7 -10.221	-4.411	-4.936	0.000	k	- T -	1	1	- T
Gueniche et al. 2008	-0.390	0.283	0.08	0 -0.944	0.165	-1.378	0.168	_		_		_ I
Pooled	-3.700	3.460	11.97	1 -10.481	3.081	-1.069	0.285	k	-			1
								1.00	0.50		0.50	
								-1.00	-0.50	0.00	0.50	1.00
									Throad 2		Freedom B	=
Study name	Statistics for each study							Hedges's g and 95% CI				
	Hedges's g	Variance	Lower	Standard error	Upper limit	Z-Value	p-Value					
Butler et al, 2020	0.371	0.114	-0.291	0.338	1.034	1.099	0.272	1.	- 1 -			
Gueniche et al, 2008	-0.708	0.081	-1.266	0.285	-0.150	-2.488	0.013	K		- 1		- C
Seite et al, 2017	-0.472	0.087	-1.049	0.294	0.105	-1.604	0.109	K	-	-		
Pooled	-0.292	0.098	-0.904	0.312	0.321	-0.934	0.350	-			-	
								-1.00	-0.50	0.00	0.50	1.00
									100000000		-CINT 832 CT	

Flint et al

16

Fig. 4. Prediction intervals for dermatitis at baseline and at four weeks—a two-week prediction model could not be created because a minimum sample size of 3 is required, (A) Prediction interval for baseline values. (B) Prediction interval for four-week values.



The mean effect size is -0.29 with a 95% confidence interval of -0.90 to 0.32 The true effect size in 95% of all comparable populations falls in the interval -7.22 to 6.64

Flint et al

17

TABLE LEGENDS

Table I. Inclusion and Exclusion Criteria

Inclusion	Exclusion
Subject age of 18 years or older ¹	Systematic Reviews/Review Articles
Randomized Control Trial	Published Before 2007
Placebo	Receiving Other Treatments Targeted at Symptoms of Atopic Dermatitis
Use of SCORAD	Symptoms of Atopic Dermatitis
Human Subjects	
Topical Probiotic(s)	
English Language	

¹This criterion was removed for the second pass of the literature review

Flint et al

18

Table II. Summary of all included articles

Study	Probiotic	Duration of Study/ Days SCORAD Measured	n / Age Range of Subjects in years (placebo, treatment)	Percent Change from Baseline in SCORAD	Additional Findings		
Noll et al, 2021	Mixture (Bifidobacterium breve, Bifidobacterium animalis lactis, Lactobacillus casei, L. gasszeri, L. planatarum, L. rhamnosus)	2 weeks/ 0,9,11,14	7,7/5+	Synbiotic baths: -40.7%, 49.7% and-56.8% on days 9, 11, and 14, respectively. Analysis of skin flora showed successful colonizz bacteria from the probiotic treatment, but the abu Staphylococcus aureus did not significantly chan Subjects in probiotic group subjectively reported less dryness at the end of study compared to cont +7.1% on days 9, 11, and 14, respectively.			
Butler et al, 2020	Lactobacillus reuteri DSM17938	8 weeks/ 0,28,56	17,17 / 19-66, 19-57	Probiotic ointment: -27.7% and -45.7% on days 28 and 56, respectively. Placebo: -31.9% and -41.0% on days 28 and 56, respectively.	Improvement of skin dryness in the probiotic group was the most pronounced change during the study.		
Gueniche et al, 2008	Vitreoscilla filiformis	4 weeks/ 0,15,29	25,26 / 6-70, 6-70	Probiotic cream: -29.7% and -56.1% on days 15 and 29, respectively. Placebo: -7.8% and -16.3% on days 15 and 29, respectively.	Probiotic group showed significantly greater reduction in SCORAD when compared to control at days 15 and 29. Skin barrier function <u>was measured</u> using the biomarker TEWL. There was a significant reduction in TEWL in both groups from their baseline values at the end of the study, but there was no significant difference between the probiotic vs control. The group treated with probiotic had decreased colonization of <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> compared to control at the end of the study, but the finding was not statistically significant.		
Seite et al, 2017	Vitreoscilla filiformis (LRP- VFB)	4 weeks/ 1,28	22,24 / 0-63, 0- 63	Probiotic cream: -15.5% on day 28. Placebo: +32.0% on day 28.	The probiotic group had significantly increased levels of Xanthomonas at the end of the study compared to control. Colonization with Staphylococcus aureus increased in the control group, but not the treatment group. The difference was not statistically significant		